Immunotherapy plus radiation before lung cancer surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests whether giving a combination of the immunotherapy drug tislelizumab and chest radiation before surgery can improve outcomes for people with early-stage, operable lung cancer. The goal is to find out if this approach helps shrink the tumor and makes surgery more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have not had any prior cancer treatment for this lung cancer.
- Your cancer is stage IB, II, or IIIA (doctors believe it can be surgically removed).
- You are between 18 and 70 years old.
- You are healthy enough to have surgery (adequate lung function and overall health).
- You are willing to provide a tumor sample for PD-L1 testing.
- If you could become pregnant, you must agree to use effective birth control during treatment and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and standard chemotherapy) given before and after surgery for people with stage II to IIIB non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach can improve outcomes for patients who can have their tumor removed.
This trial tests a combination of radiation, immunotherapy (QL1706), and chemotherapy given before surgery for non-small-cell lung cancer that can be removed. It aims to see if this approach can shrink the tumor and improve outcomes.
This trial tests a combination of low-dose radiation, an immunotherapy drug called sintilimab, and standard chemotherapy before surgery for stage II–III non-small cell lung cancer (NSCLC). The goal is to see if this approach can shrink tumors and improve outcomes for patients who are candidates for surgery.
This trial tests whether combining radiation, an immunotherapy drug (toripalimab), and chemotherapy before surgery can help shrink tumors and improve outcomes in people with resectable stage II to III non-small cell lung cancer. It aims to see if this approach works better than standard chemotherapy alone.
This trial tests whether giving an immune-boosting drug (Tα1) along with chemotherapy and immunotherapy before surgery helps people with stage II-IIIB non-small cell lung cancer that can be removed. It aims to see if this combination makes the cancer shrink more and improves outcomes.
This trial tests a combination of targeted radiation (SBRT), an immunotherapy drug (tislelizumab), and a targeted therapy (anlotinib) given before surgery for people with a certain type of lung cancer that has not spread too far. It aims to see if this approach can shrink the tumor and improve outcomes.
Hear when a new Resectable NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.